We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AnaSpec Offers ClearPoint™ ß-Amyloid Custom Peptide Synthesis Service

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Offers ClearPoint™ ß-Amyloid Custom Peptide Synthesis Service"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaSpec, the world’s largest provider of β-amyloid peptide and Alzheimer’s research reagents, also provides ClearPoint™ β-Amyloid custom peptide synthesis service.

ClearPoint™ peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids.

ClearPoint™ peptides offer a choice of heavy carbon (13C), or nitrogen (15N)-isotopes specifically labeled at single or universal positions.

With over 10 years of successful synthesis, ClearPoint™ peptides are the proven solution for optimum quality heavy isotope labeled peptides.

These peptides can be used for the quantitative analyses of β-amyloid peptides in biological fluids using mass spectrometry (MS).

The inclusion of internal heavy isotope labeled peptide standards makes mass spectrometry an absolute quantitation (AQUA) method for the peptide of interest.

β-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD). Historically, ELISA assays have been used in the quantitation of these peptides.

However, technical challenges such as the tendency of β-amyloid (1-40) and (1-42) peptides to self-aggregate, undergo post-translational modifications or bind to other proteins often result in inaccuracies in quantitation when using ELISA.2 Oe, et al. reported the use of [15N]-labeled β-Amyloid peptides as internal standards using immunoaffinity purified CSF.